Lifesci Capital Has Optimistic View of CNTA FY2025 Earnings

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) – Stock analysts at Lifesci Capital increased their FY2025 earnings estimates for Centessa Pharmaceuticals in a research report issued to clients and investors on Thursday, November 13th. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings per share of ($1.37) for the year, up from their previous estimate of ($1.39). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Lifesci Capital also issued estimates for Centessa Pharmaceuticals’ Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.61) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02).

A number of other equities analysts also recently issued reports on CNTA. Oppenheimer began coverage on Centessa Pharmaceuticals in a research report on Friday, August 29th. They set an “outperform” rating and a $40.00 price objective for the company. Chardan Capital restated a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, October 8th. Truist Financial set a $30.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, November 5th. Finally, Guggenheim lifted their target price on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.78.

Centessa Pharmaceuticals Stock Up 3.8%

Shares of CNTA opened at $28.36 on Monday. The stock’s 50-day moving average price is $23.51 and its two-hundred day moving average price is $17.76. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $29.29. The company has a market capitalization of $3.81 billion, a PE ratio of -15.50 and a beta of 1.56. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36.

Insider Activity

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 8,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, October 27th. The shares were sold at an average price of $25.00, for a total value of $200,000.00. Following the completion of the sale, the insider directly owned 194,394 shares of the company’s stock, valued at approximately $4,859,850. The trade was a 3.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the company’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $22.41, for a total transaction of $134,460.00. Following the transaction, the general counsel owned 105,386 shares in the company, valued at $2,361,700.26. This represents a 5.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 179,964 shares of company stock worth $4,106,481 in the last quarter. 7.09% of the stock is owned by corporate insiders.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC bought a new stake in shares of Centessa Pharmaceuticals during the second quarter worth about $218,000. Cutter Capital Management LP boosted its stake in Centessa Pharmaceuticals by 184.3% during the 1st quarter. Cutter Capital Management LP now owns 418,127 shares of the company’s stock valued at $6,013,000 after purchasing an additional 271,051 shares during the last quarter. American Century Companies Inc. boosted its stake in Centessa Pharmaceuticals by 1.2% during the 1st quarter. American Century Companies Inc. now owns 1,092,754 shares of the company’s stock valued at $15,714,000 after purchasing an additional 13,046 shares during the last quarter. Cerity Partners LLC bought a new stake in Centessa Pharmaceuticals during the 1st quarter worth approximately $471,000. Finally, Wellington Management Group LLP raised its stake in shares of Centessa Pharmaceuticals by 20.6% in the first quarter. Wellington Management Group LLP now owns 138,767 shares of the company’s stock worth $1,995,000 after purchasing an additional 23,660 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.